Publication Information

{'id': 'https://openalex.org/W4282962473', 'doi': 'https://doi.org/10.1158/1538-7445.am2022-651', 'title': 'Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models', 'display_name': 'Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models', 'publication_year': 2022, 'publication_date': '2022-06-15', 'ids': {'openalex': 'https://openalex.org/W4282962473', 'doi': 'https://doi.org/10.1158/1538-7445.am2022-651'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2022-651', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5028185404', 'display_name': 'Tatsuo Sugawara', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210144383', 'display_name': 'Nuvisan (Germany)', 'ror': 'https://ror.org/039kzrb23', 'country_code': 'DE', 'type': 'company', 'lineage': ['https://openalex.org/I4210144383']}], 'countries': ['DE'], 'is_corresponding': False, 'raw_author_name': 'Tatsuo Sugawara', 'raw_affiliation_strings': ['1Nuvisan GmBH, Berlin, Germany;'], 'affiliations': [{'raw_affiliation_string': '1Nuvisan GmBH, Berlin, Germany;', 'institution_ids': ['https://openalex.org/I4210144383']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5002466627', 'display_name': 'Holly M. Nguyen', 'orcid': 'https://orcid.org/0000-0002-6331-8089'}, 'institutions': [{'id': 'https://openalex.org/I201448701', 'display_name': 'University of Washington', 'ror': 'https://ror.org/00cvxb145', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I201448701']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Holly NGuyen', 'raw_affiliation_strings': ['2University of Washington, Seattle, WA;'], 'affiliations': [{'raw_affiliation_string': '2University of Washington, Seattle, WA;', 'institution_ids': ['https://openalex.org/I201448701']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5018745405', 'display_name': 'Eva Corey', 'orcid': 'https://orcid.org/0000-0002-9244-3807'}, 'institutions': [{'id': 'https://openalex.org/I201448701', 'display_name': 'University of Washington', 'ror': 'https://ror.org/00cvxb145', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I201448701']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Eva Corey', 'raw_affiliation_strings': ['2University of Washington, Seattle, WA;'], 'affiliations': [{'raw_affiliation_string': '2University of Washington, Seattle, WA;', 'institution_ids': ['https://openalex.org/I201448701']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5029670475', 'display_name': 'Ekaterina Nevedomskaya', 'orcid': None}, 'institutions': [], 'countries': ['DE'], 'is_corresponding': False, 'raw_author_name': 'Ekaterina Nevedomskaya', 'raw_affiliation_strings': ['3Bayer AG, Berlin, Germany.'], 'affiliations': [{'raw_affiliation_string': '3Bayer AG, Berlin, Germany.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5056198089', 'display_name': 'Oliver Politz', 'orcid': 'https://orcid.org/0000-0002-0272-6249'}, 'institutions': [], 'countries': ['DE'], 'is_corresponding': False, 'raw_author_name': 'Oliver Politz', 'raw_affiliation_strings': ['3Bayer AG, Berlin, Germany.'], 'affiliations': [{'raw_affiliation_string': '3Bayer AG, Berlin, Germany.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5009359386', 'display_name': 'Dominik Mumberg', 'orcid': 'https://orcid.org/0000-0002-6670-1497'}, 'institutions': [], 'countries': ['DE'], 'is_corresponding': False, 'raw_author_name': 'Dominik Mumberg', 'raw_affiliation_strings': ['3Bayer AG, Berlin, Germany.'], 'affiliations': [{'raw_affiliation_string': '3Bayer AG, Berlin, Germany.', 'institution_ids': []}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5048300451', 'display_name': 'Bernard Haendler', 'orcid': 'https://orcid.org/0000-0002-4490-0663'}, 'institutions': [], 'countries': ['DE'], 'is_corresponding': False, 'raw_author_name': 'Bernard Haendler', 'raw_affiliation_strings': ['3Bayer AG, Berlin, Germany.'], 'affiliations': [{'raw_affiliation_string': '3Bayer AG, Berlin, Germany.', 'institution_ids': []}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 2, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.505, 'has_fulltext': False, 'cited_by_count': 2, 'citation_normalized_percentile': {'value': 0.526625, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 70, 'max': 76}, 'biblio': {'volume': '82', 'issue': '12_Supplement', 'first_page': '651', 'last_page': '651'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10543', 'display_name': 'Prostate Cancer Treatment and Research', 'score': 0.999, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10543', 'display_name': 'Prostate Cancer Treatment and Research', 'score': 0.999, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12465', 'display_name': 'Cancer, Lipids, and Metabolism', 'score': 0.9753, 'subfield': {'id': 'https://openalex.org/subfields/1306', 'display_name': 'Cancer Research'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T12829', 'display_name': 'Advanced Breast Cancer Therapies', 'score': 0.9234, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/enzalutamide', 'display_name': 'Enzalutamide', 'score': 0.42157763}], 'concepts': [{'id': 'https://openalex.org/C2780192828', 'wikidata': 'https://www.wikidata.org/wiki/Q181257', 'display_name': 'Prostate cancer', 'level': 3, 'score': 0.79350364}, {'id': 'https://openalex.org/C86554907', 'wikidata': 'https://www.wikidata.org/wiki/Q285613', 'display_name': 'PI3K/AKT/mTOR pathway', 'level': 3, 'score': 0.6438055}, {'id': 'https://openalex.org/C61367390', 'wikidata': 'https://www.wikidata.org/wiki/Q416601', 'display_name': 'Androgen receptor', 'level': 4, 'score': 0.6410959}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.62900984}, {'id': 'https://openalex.org/C2777609662', 'wikidata': 'https://www.wikidata.org/wiki/Q416356', 'display_name': 'PTEN', 'level': 4, 'score': 0.60581386}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.58166325}, {'id': 'https://openalex.org/C75217442', 'wikidata': 'https://www.wikidata.org/wiki/Q423650', 'display_name': 'Protein kinase B', 'level': 3, 'score': 0.49301168}, {'id': 'https://openalex.org/C2776551883', 'wikidata': 'https://www.wikidata.org/wiki/Q1996756', 'display_name': 'Enzalutamide', 'level': 5, 'score': 0.42157763}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.41467777}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.36499417}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.33271363}, {'id': 'https://openalex.org/C185592680', 'wikidata': 'https://www.wikidata.org/wiki/Q2329', 'display_name': 'Chemistry', 'level': 0, 'score': 0.23396212}, {'id': 'https://openalex.org/C62478195', 'wikidata': 'https://www.wikidata.org/wiki/Q828130', 'display_name': 'Signal transduction', 'level': 2, 'score': 0.22105938}, {'id': 'https://openalex.org/C55493867', 'wikidata': 'https://www.wikidata.org/wiki/Q7094', 'display_name': 'Biochemistry', 'level': 1, 'score': 0.0}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2022-651', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.85, 'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4362621709', 'https://openalex.org/W4362609326', 'https://openalex.org/W4362609250', 'https://openalex.org/W4362495275', 'https://openalex.org/W4362495086', 'https://openalex.org/W4361940014', 'https://openalex.org/W4361890616', 'https://openalex.org/W2991319487', 'https://openalex.org/W2890810587', 'https://openalex.org/W2737056430'], 'abstract_inverted_index': {'Abstract': [0], 'Prostate': [1], 'cancer': [2, 57, 82, 96, 153, 258, 325, 388, 427], 'is': [3, 59, 73], 'mainly': [4], 'driven': [5], 'by': [6, 240], 'androgen': [7, 235, 409], 'receptor': [8, 410], '(AR)': [9], 'signaling': [10, 49, 383], 'so': [11, 187], 'that': [12, 148, 197, 227, 233, 253, 314], 'drugs': [13], 'directly': [14], 'inhibiting': [15, 85], 'this': [16], 'pathway': [17, 50, 70, 224], 'such': [18, 204], 'as': [19, 28, 205], 'GnRH': [20], 'ligands': [21], 'and': [22, 36, 58, 98, 143, 158, 176, 185, 208, 244, 338, 381, 413, 423], 'AR': [23, 117, 127, 201, 380], 'inhibitors': [24, 104, 384], 'are': [25, 105, 360], 'now': [26], 'established': [27], 'mainstay': [29], 'treatments.': [30], 'Unfortunately,': [31], 'treatment': [32, 182, 189, 236, 274, 297], 'resistance': [33], 'often': [34, 113], 'develops': [35], 'combination': [37, 115, 305], 'therapies': [38], 'may': [39], 'represent': [40], 'potential': [41], 'strategies': [42], 'to': [43, 77, 270, 332, 362, 419], 'prolong': [44], 'disease': [45], 'remission.': [46], 'The': [47], 'PI3K/Akt/mTOR': [48, 69], 'plays': [51], 'an': [52], 'essential': [53], 'role': [54], 'in': [55, 61, 75, 93, 108, 114, 141, 144, 172, 221, 248, 327, 349, 356, 385, 425], 'prostate': [56, 81, 95, 111, 152, 257, 324, 387, 426], 'upregulated': [60], 'about': [62], '30-50%': [63], 'of': [64, 67, 79, 124, 168, 230, 323, 335, 340, 375, 378, 407, 432], 'patients.': [65, 83, 389], 'Loss': [66], 'the': [68, 122, 126, 131, 173, 222, 228, 241, 254, 283, 304, 321, 350, 364, 373, 376, 408, 414, 433], 'inhibitor': [71, 128, 136, 411, 416], 'PTEN': [72, 266, 290], 'observed': [74, 171, 348], 'up': [76], '40%': [78], 'late-stage': [80, 386], 'Compounds': [84], 'PI3K': [86, 135, 382, 415], 'or': [87, 295], 'Akt': [88], 'have': [89], 'shown': [90], 'promising': [91], 'efficacy': [92, 250, 345, 422], 'preclinical': [94, 139], 'models,': [97], 'advanced': [99], 'clinical': [100], 'trials': [101], 'with': [102, 116, 130, 156, 183, 190, 275, 317], 'these': [103, 369], 'currently': [106], 'ongoing': [107], 'metastatic': [109], 'castration-resistant': [110], 'cancer,': [112], 'inhibitors.': [118], 'Here': [119], 'we': [120, 225, 312], 'examined': [121], 'impact': [123, 377], 'combining': [125, 315, 379], 'darolutamide': [129, 157, 198, 243, 294, 316, 412], 'pan': [132], 'class': [133], 'I': [134], 'copanlisib': [137, 159, 184, 191, 211, 245, 276, 296, 318, 417], 'on': [138], 'models': [140, 326, 428], 'vitro': [142], 'vivo.': [145, 357], 'We': [146], 'found': [147, 226, 313], 'treating': [149], 'different': [150], 'androgen-dependent': [151], 'cell': [154, 336], 'lines': [155], 'had': [160, 212], 'a': [161, 264], 'very': [162], 'strong': [163, 333], 'synergistic': [164], 'inhibitory': [165, 308], 'effect.': [166], 'Induction': [167], 'apoptosis': [169, 337, 424], 'was': [170, 237, 330, 346], 'PARP': [174], 'cleavage': [175], 'caspase': [177], '3/7': [178], 'activation': [179], 'assays': [180], 'after': [181, 188], 'more': [186], 'plus': [192], 'darolutamide.': [193], 'Expression': [194], 'analysis': [195], 'showed': [196, 252, 299], 'strongly': [199, 238, 268, 319], 'down-regulated': [200], 'target': [202], 'genes': [203, 219, 232], 'KLK3,': [206], 'FKBP5': [207], 'TMPRSS2,': [209], 'but': [210, 272], 'no': [213], 'additional': [214, 273], 'impact.': [215], 'However,': [216], 'when': [217], 'examining': [218], 'involved': [220], 'apoptotic': [223], 'down-regulation': [229], 'pro-apoptotic': [231, 341], 'follows': [234], 'reversed': [239], 'combined': [242], 'treatment.': [246], 'Finally,': [247], 'vivo': [249], 'studies': [251], 'LuCaP': [255, 284, 351], '96': [256], 'patient-derived': [259], '(PDX)': [260], 'xenograft,': [261], 'which': [262, 288], 'has': [263], 'non-functional': [265], 'gene,': [267], 'responded': [269], 'darolutamide,': [271], 'did': [277], 'not': [278], 'increase': [279], 'anti-tumor': [280, 421], 'efficacy.': [281], 'In': [282, 310], '35': [285, 352], 'PDX': [286, 353], 'model,': [287], 'expresses': [289], 'at': [291], 'low': [292], 'level,': [293], 'alone': [298], 'only': [300], 'limited': [301], 'efficacy,': [302], 'while': [303], 'exhibited': [306], 'tumor': [307], 'effects.': [309], 'conclusion,': [311], 'inhibited': [320], 'proliferation': [322], 'vitro.': [328], 'This': [329], 'linked': [331], 'induction': [334], 'prevention': [339], 'gene': [342], 'down-regulation.': [343], 'Superior': [344], 'also': [347], 'xenograft': [354], 'model': [355], 'Additional': [358], 'data': [359], 'needed': [361], 'explore': [363], 'underlying': [365], 'molecular': [366], 'mechanisms.': [367], 'Together': [368], 'results': [370], 'further': [371], 'support': [372], 'exploration': [374], 'Citation': [390], 'Format:': [391], 'Tatsuo': [392], 'Sugawara,': [393], 'Holly': [394], 'NGuyen,': [395], 'Eva': [396], 'Corey,': [397], 'Ekaterina': [398], 'Nevedomskaya,': [399], 'Oliver': [400], 'Politz,': [401], 'Dominik': [402], 'Mumberg,': [403], 'Bernard': [404], 'Haendler.': [405], 'Combination': [406], 'leads': [418], 'improved': [420], '[abstract].': [429], 'In:': [430], 'Proceedings': [431], 'American': [434], 'Association': [435], 'for': [436], 'Cancer': [437, 448], 'Research': [438], 'Annual': [439], 'Meeting': [440], '2022;': [441], '2022': [442], 'Apr': [443], '8-13.': [444], 'Philadelphia': [445], '(PA):': [446], 'AACR;': [447], 'Res': [449], '2022;82(12_Suppl):Abstract': [450], 'nr': [451], '651.': [452]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4282962473', 'counts_by_year': [{'year': 2023, 'cited_by_count': 2}], 'updated_date': '2024-12-15T14:50:01.830408', 'created_date': '2022-06-17'}